• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Quantum-Si Reports Second Quarter 2021 Financial Results

    8/16/21 4:05:00 PM ET
    $CAPA
    $QSI
    Business Services
    Finance
    Industrial Machinery/Components
    Industrials
    Get the next $CAPA alert in real time by email

    Quantum-Si Solidifies Financial Strength and Continues Systematic Commercialization Strategy

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si" or the "Company"), a company pioneering next-generation semiconductor chip-based proteomics, today announced financial results for the quarter ended June 30, 2021 and provided a business update. John Stark, Quantum-Si's Chief Executive Officer, and Claudia Drayton, Quantum-Si's Chief Financial Officer, will host a call today at 4:30 pm EDT to review the Company's results.

    Recent Highlights:

    • Completed the business combination with HighCape Capital Acquisition Corp. ("HighCape"), adding over $511 million in cash to the balance sheet.
    • Successfully delivered three additional early access systems to key thought leaders in proteomics and single-molecule sequencing to support product development.
    • Entered into an agreement to develop a state-of-the-art, 25,000 square foot facility in San Diego to support production and research and development activities.
    • Increased headcount to support future growth; senior-level appointments include our Chief Financial Officer and Head of People.

    "The second quarter was a pivotal one for Quantum-Si. We completed the business combination with HighCape, securing funding for future growth and commercial expansion," said John Stark, Quantum-Si's Chief Executive Officer. "We have now delivered a total of 5 systems under our early access program to key thought leaders. We are actively partnering with these groups to conduct studies demonstrating the power of single-molecule protein sequencing. We continue to scale our company to support future growth, adding significantly to headcount and recently entering into an agreement to develop a 25,000 square feet state-of-the-art facility in San Diego. These developments will help drive our commercialization efforts and position Quantum-Si as a leader in the highly anticipated field of single-molecule protein sequencing. I'm honored to lead this talented organization through the next step in our evolution."

    Second Quarter 2021 Financial Results

    Operating expenses were $32.2 million in the second quarter of 2021, compared to $8.2 million in the second quarter of 2020, representing an increase of 292%.

    Research and development expenses for the second quarter of 2021 were $13.1 million compared to $6.6 million in the second quarter of 2020.

    Selling, general and administrative expenses for the second quarter of 2021 were $19.1 million compared to $1.6 million in the second quarter of 2020.

    Net loss for the second quarter of 2021 was $35.7 million compared to a net loss of $8.2 million during the second quarter of 2020. Adjusted EBITDA was negative $14.6 million in the second quarter of 2021 compared with negative $7.5 million in the same period in 2020. Please see the reconciliation of non-GAAP Adjusted EBITDA to net loss below.

    As of June 30, 2021, cash and cash equivalents were $521.9 million.

    Conference Call

    A conference call to review the second quarter 2021 financial results is scheduled for August 16, 2021, at 4:30 PM Eastern Time. Interested parties may access the conference call by dialing (844) 200-6205 (U.S.) or +44 208 0682-558 (International) and using access code 455685. A replay of the call will be available until August 23, 2021 using the link posted to the Events & Presentations section of Quantum-Si's website.

    About Quantum-Si Incorporated

    Founded by Dr. Jonathan Rothberg in 2013, Quantum-Si is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

    Non-GAAP Financial Measures

    In addition to providing financial measurements that have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), the Company provides additional financial metrics that are not prepared in accordance with U.S. GAAP ("non-GAAP"). The non-GAAP financial measure included in this press release is Adjusted EBITDA. The Company presents non-GAAP financial measures in order to assist readers of its condensed consolidated financial statements in understanding the core operating results that its management uses to evaluate the business and for financial planning purposes. The Company's non-GAAP financial measure, Adjusted EBITDA, provides an additional tool for investors to use in comparing its financial performance over multiple periods.

    Adjusted EBITDA is a key performance measure that the Company's management uses to assess its operating performance. This non-GAAP measure facilitates internal comparisons of the Company's operating performance on a more consistent basis. The Company uses this performance measure for business planning purposes and forecasting. The Company believes that Adjusted EBITDA enhances an investor's understanding of the Company's financial performance as it is useful in assessing its operating performance from period-to-period by excluding certain items that the Company believes are not representative of its core business.

    Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate this measure in the same manner. Adjusted EBITDA is not prepared in accordance with U.S. GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with U.S. GAAP. When evaluating the Company's performance, you should consider Adjusted EBITDA alongside other financial performance measures prepared in accordance with U.S. GAAP, including net loss.

    The non-GAAP financial measure does not replace the presentation of the Company's U.S. GAAP financial results and should only be used as a supplement to, not as a substitute for, the Company's financial results presented in accordance with U.S. GAAP. In this press release, the Company has provided a reconciliation of Adjusted EBITDA to net loss, the most directly comparable U.S. GAAP financial measure. A reconciliation of Adjusted EBITDA to corresponding U.S. GAAP measures is not available on a forward-looking basis because the Company is unable to predict with reasonable certainty the non-cash component of employee compensation expense, changes in its working capital needs, the impact of earnings or charges resulting from matters the Company considers not to be reflective, on a recurring basis, of its ongoing operations, and other such items without unreasonable effort. These items are uncertain, depend on various factors, and could be material to the Company's results computed in accordance with U.S. GAAP. Management strongly encourages investors to review the Company's financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development of products and services. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's shares of Class A common stock on The Nasdaq Stock Market LLC; the ability to recognize the anticipated benefits of the recently completed business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development activities; the potential attributes and benefits of the Company's products and services; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is developing; the size and growth potential of the markets for the Company's future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services following anticipated commercial launch; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

    QUANTUM-SI INCORPORATED

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (in thousands, except share and per share amounts)

    (Unaudited)

     
    Three months ended June 30, Six months ended June 30,

    2021

    2020

    2021

    2020

    Operating expenses:
    Research and development

    $

    13,114

     

    $

    6,595

     

    $

    21,086

     

    $

    14,519

     

    General and administrative

     

    17,805

     

     

    1,306

     

     

    21,222

     

     

    3,526

     

    Sales and marketing

     

    1,245

     

     

    300

     

     

    1,635

     

     

    559

     

    Total operating expenses

     

    32,164

     

     

    8,201

     

     

    43,943

     

     

    18,604

     

    Loss from operations

     

    (32,164

    )

     

    (8,201

    )

     

    (43,943

    )

     

    (18,604

    )

    Interest income

     

    2

     

     

    7

     

     

    2

     

     

    93

     

    Interest expense

     

    (5

    )

     

    (1

    )

     

    (5

    )

     

    (1

    )

    Change in fair value of warrant liabilities

     

    (3,533

    )

     

    -

     

     

    (3,533

    )

     

    -

     

    Other income (expense), net

     

    3

     

     

    (2

    )

     

    3

     

     

    1

     

    Loss before provision for income taxes

     

    (35,697

    )

     

    (8,197

    )

     

    (47,476

    )

     

    (18,511

    )

    Provision for income taxes

     

    -

     

     

    -

     

     

    -

     

     

    -

     

    Net loss and comprehensive loss

    $

    (35,697

    )

    $

    (8,197

    )

    $

    (47,476

    )

    $

    (18,511

    )

    Net loss per common share attributable to common stockholders, basic and diluted

    $

    (3.05

    )

    $

    (1.53

    )

    $

    (5.50

    )

    $

    (3.46

    )

    Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted

     

    11,696,084

     

     

    5,351,199

     

     

    8,629,355

     

     

    5,345,854

     

    QUANTUM-SI INCORPORATED

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands, except share and per share amounts)

    (Unaudited)

     
    June 30, December 31,

    2021

    2020

    Assets
    Current assets:
    Cash and cash equivalents

    $

    521,936

     

    $

    36,910

     

    Prepaid expenses and other current assets

     

    2,007

     

     

    716

     

    Due from related parties

     

    150

     

     

    232

     

    Total current assets

     

    524,093

     

     

    37,858

     

    Property and equipment, net

     

    2,857

     

     

    1,996

     

    Other assets - related party

     

    -

     

     

    738

     

    Total assets

    $

    526,950

     

    $

    40,592

     

    Liabilities, convertible preferred stock and stockholders' equity (deficit)
    Current liabilities:
    Accounts payable

    $

    3,032

     

    $

    1,301

     

    Due to related parties

     

    886

     

     

    28

     

    Accrued expenses and other current liabilities

     

    3,946

     

     

    1,425

     

    Total current liabilities

     

    7,864

     

     

    2,754

     

    Long-term liabilities:
    Warrant liabilities

     

    15,150

     

     

    -

     

    Notes payable

     

    -

     

     

    1,749

     

    Total liabilities

     

    23,014

     

     

    4,503

     

    Commitments and contingencies
    Convertible preferred stock
    Convertible preferred stock (Series A, B, C, D, and E) $0.0001 par value with an aggregate liquidation preference of $0 and $216 as of June 30, 2021 and December 31, 2020, respectively; 0 and 92,078,549 shares authorized as of June 30, 2021 and December 31, 2020, respectively; 0 and 90,789,268 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively

     

    -

     

     

    195,814

     

    Stockholders' equity (deficit)
    Class A Common stock, $0.0001 par value; 600,000,000 and 90,000,000 shares authorized as of June 30, 2021 and December 31, 2020, respectively; 116,463,160 and 5,378,287 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively

     

    12

     

     

    1

     

    Class B Common stock, $0.0001 par value; 27,000,000 and 0 shares authorized as of June 30, 2021 and December 31, 2020, respectively; 19,937,500 and 0 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively

     

    2

     

     

    -

     

    Additional paid-in capital

     

    723,641

     

     

    12,517

     

    Accumulated deficit

     

    (219,719

    )

     

    (172,243

    )

    Total stockholders' equity (deficit)

     

    503,936

     

     

    (159,725

    )

    Total Liabilities, convertible preferred stock and stockholders' equity (deficit)

    $

    526,950

    $

    40,592

     

    QUANTUM-SI INCORPORATED

    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

    (in thousands)

    (Unaudited)

     

    Adjusted EBITDA

     
    Three Months Ended June 30, Six Months Ended June 30,

    2021

    2020

    2021

    2020

    Net loss

    $

    (35,697

    )

    $

    (8,197

    )

    $

    (47,476

    )

    $

    (18,511

    )

    Interest income

     

    (2

    )

     

    (7

    )

     

    (2

    )

     

    (93

    )

    Interest expense

     

    5

     

     

    1

     

     

    5

     

     

    1

     

    Change in fair value of warrant liabilities

     

    3,533

     

     

    -

     

     

    3,533

     

     

    -

     

    Other (income) expense, net

     

    (3

    )

     

    2

     

     

    (3

    )

     

    (1

    )

    Stock-based compensation expense

     

    9,987

     

     

    466

     

     

    10,444

     

     

    1,108

     

    Depreciation and amortization

     

    235

     

     

    225

     

     

    448

     

     

    454

     

    Transaction related costs

     

    7,383

     

     

    -

     

     

    7,383

     

     

    -

     

    Adjusted EBITDA

    $

    (14,559

    )

    $

    (7,510

    )

    $

    (25,668

    )

    $

    (17,042

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210816005591/en/

    Get the next $CAPA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAPA
    $QSI

    CompanyDatePrice TargetRatingAnalyst
    Quantum-Si Incorporated
    $QSI
    2/7/2025$3.75Buy
    Alliance Global Partners
    Quantum-Si Incorporated
    $QSI
    12/8/2023$3.00Buy
    H.C. Wainwright
    Quantum-Si Incorporated
    $QSI
    9/25/2023$3.50 → $2.00Buy → Hold
    Canaccord Genuity
    Quantum-Si Incorporated
    $QSI
    10/20/2021$13.00Buy
    Canaccord Genuity
    More analyst ratings

    $CAPA
    $QSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on Quantum-Si with a new price target

      Alliance Global Partners initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.75

      2/7/25 8:29:38 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • H.C. Wainwright initiated coverage on Quantum-Si with a new price target

      H.C. Wainwright initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.00

      12/8/23 7:55:31 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Quantum-Si from Buy to Hold and set a new price target of $2.00 from $3.50 previously

      9/25/23 9:04:14 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $CAPA
    $QSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Quantum-Si Incorporated

      SC 13D/A - Quantum-Si Inc (0001816431) (Subject)

      9/17/24 4:24:56 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Quantum-Si Incorporated

      SC 13G/A - Quantum-Si Inc (0001816431) (Subject)

      6/28/24 5:16:32 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G filed by Quantum-Si Incorporated

      SC 13G - Quantum-Si Inc (0001816431) (Subject)

      2/13/24 9:41:18 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $CAPA
    $QSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CAPA
    $QSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chief Financial Officer Keyes Jeffry R. bought $43,465 worth of shares (50,000 units at $0.87), increasing direct ownership by 13% to 446,820 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:25 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • President & CEO Hawkins Jeffrey Alan bought $21,272 worth of shares (25,000 units at $0.85), increasing direct ownership by 3% to 1,003,757 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:28 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Director Kummeth Charles R. bought $148,459 worth of shares (170,000 units at $0.87), increasing direct ownership by 92% to 355,000 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:24 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Reports First Quarter 2025 Financial Results

      Launches and Delivers First Platinum® Pro Units Announces New Library Preparation Development Program Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the first quarter ended March 31, 2025. Press Release Highlights First quarter 2025 revenue of $842,000, an 84% increase over the first quarter of 2024 Launched and completed first deliveries of Platinum® Pro Announced on track development of Proteus™ Platform and v4 Sequencing Kit Announced development of a new v3 Library Preparation Kit with expected launch by end of 2025 Expands international channel network Reaffirms cash runw

      5/15/25 4:05:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Dr. Gloria Sheynkman from the University of Virginia to Present Pioneering Research utilizing Quantum-Si's Next-Gen Protein Sequencing™ Platform in Upcoming Nature Webinar on May 15

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, is pleased to announce an upcoming Nature webinar featuring Gloria Sheynkman, Ph.D., Associate Professor, University of Virginia, who will present new findings from her recent preprint on sequencing proteoform variation with Next-Gen Protein Sequencing™ (NGPS™). The live webinar will take place on May 15, 2025, at 8:00 a.m. PDT / 11:00 a.m. EDT. Proteins are central to cellular function, yet traditional proteomics methods, including mass spectrometry and affinity-based approaches, face challenges in resolving proteoforms, the distinct molecular variation arising from alternative sp

      5/12/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si to Report First Quarter 2025 Financial Results on May 15, 2025

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the first quarter 2025 on Thursday, May 15, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personali

      4/24/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $CAPA
    $QSI
    Leadership Updates

    Live Leadership Updates

    See more
    • Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024. Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Ku

      5/30/24 4:05:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321183506/en/Paula Dowdy (Photo: Business Wire) Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation tools company based in the UK and is an advisor at EQT Life Sciences, one of Europe's leading investors targeting innovative

      3/21/24 4:05:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Introduces World's First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein sequencer™ and associated consumables throughout Japan. "Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences. We're poised to empower Japanese researchers wit

      1/18/24 8:30:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $CAPA
    $QSI
    Financials

    Live finance-specific insights

    See more

    $CAPA
    $QSI
    SEC Filings

    See more
    • Quantum-Si to Report First Quarter 2025 Financial Results on May 15, 2025

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the first quarter 2025 on Thursday, May 15, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personali

      4/24/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results

      Achieves First Quarterly Revenue Over $1 Million Completes Capital Raises of $86 Million Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the fourth quarter and full year ended December 31, 2024. Press Release Highlights Reported revenue of $1.2 million for the fourth quarter of 2024 and $3.1 million for the full year 2024 (representing a 183% full year-over-year growth) Raised capital of over $86 million between the fourth quarter of 2024 and first week of 2025 (extending cash runway into the second half of 2027) Announced the launch of Platinum® Pro in January 2025, with shipp

      3/3/25 4:05:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 3, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in numbe

      2/12/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Quantum-Si Incorporated

      SCHEDULE 13G/A - Quantum-Si Inc (0001816431) (Subject)

      6/6/25 2:58:53 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • SEC Form SD filed by Quantum-Si Incorporated

      SD - Quantum-Si Inc (0001816431) (Filer)

      5/22/25 4:05:35 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Quantum-Si Inc (0001816431) (Filer)

      5/19/25 4:05:24 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $CAPA
    $QSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Makes Brigid

      4 - Quantum-Si Inc (0001816431) (Issuer)

      5/21/25 4:01:33 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Director Kenny John P.

      4 - Quantum-Si Inc (0001816431) (Issuer)

      5/21/25 4:01:36 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Director Kummeth Charles R.

      4 - Quantum-Si Inc (0001816431) (Issuer)

      5/21/25 4:01:35 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials